Regents Of The University Of California Cytom X Therapeutics, Inc. Call Options Transaction History
Regents Of The University Of California
- $179 Million
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CTMX
# of Institutions
75Shares Held
50.5MCall Options Held
22.3KPut Options Held
22.9K-
Tang Capital Management LLC San Diego, CA7.79MShares$7.87 Million1.16% of portfolio
-
Janus Henderson Group PLC London, X06.3MShares$6.37 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$5.28 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$4.94 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3MShares$3.03 Million0.01% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $66.6M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...